

Datasheet for ABIN6952435

anti-SARS-CoV-2 Nucleocapsid antibody**3** Images**6** Publications[Go to Product page](#)

Overview

Quantity:	100 µL
Target:	SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
Reactivity:	SARS Coronavirus-2 (SARS-CoV-2), Virus
Host:	Mouse
Clonality:	Monoclonal
Application:	ELISA, Western Blotting (WB)

Product Details

Immunogen:	Recombinant SARS-CoV-2 N protein (His-tag)
Clone:	1C7
Isotype:	IgG2b
Purification:	Purified by Protein G.

Target Details

Target:	SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
Alternative Name:	SARS-CoV-2 N protein (SARS-CoV-2 N Products)
Target Type:	Viral Protein
UniProt:	P0DTC9

Application Details

Application Notes: WB 1:300-1000
ELISA 1:500-1000

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 µg/µL

Buffer: Aqueous buffered solution containing 0.01M PBS(pH 7.4) with 0.1 % Proclin300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20 °C


Expiry Date: 12 months

Publications

Product cited in: Ricard, Ciais, Levet, Subileau, Mallet, Zimmers, Lee, Bidart, Feige, Bailly: "BMP9 and BMP10 are critical for postnatal retinal vascular remodeling." in: **Blood**, Vol. 119, Issue 25, pp. 6162-71, (2012) ([PubMed](#)).


Calne, Lees: "Late progression of post-encephalitic Parkinson's syndrome." in: **The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques**, Vol. 15, Issue 2, pp. 135-8, (1988) ([PubMed](#)).

There are more publications referencing this product on: [Product page](#)




ELISA

Image 1. SARS-CoV-2 In-Cell ELISA using ABIN6952435: In-Cell ELISA was performed 24 h post infection. Dots show the mean of three technical repeats per condition from 2-3 independent experiments. Thick lines show arithmetic mean with SEM. B shows data normalized to mock treated infection controls. Source: 10.20944/preprints202207.0065.v1



ELISA

Image 2. The icELISA test allows quantification of SARS-CoV-2 replication and its inhibition by antiviral compounds. The α-N mAb1 (ABIN6952435), α-N mAb2 (ABIN6952433), α-E Ab (ABIN1031551) were used for this ELISA test. (A) Caco-2 cells were infected with indicated doses of SARS-CoV-2. At 3 d p.i., cells were fixed and detected by icELISA using E- and N-specific primary antibodies. For all further icELISAs, α-N mAb1 was used. (B) Vero E6 and Caco-2 cells were infected with indicated doses of SARS-CoV-2. At 3 d p.i., cells were analyzed by icELISA. (C) Caco-2 cells were treated with indicated concentrations of IFNα2 or IFNβ. At 3 h post treatment, cells were infected with SARS-CoV-2 (MOI 0.1). Viral replication was evaluated at 3 d p.i. by icELISA. (D–F) Vero E6 cells were infected with indicated doses of SARS-CoV-2. At 6, 15, and 22 h p.i. (D, E, and F, respectively), and cells were analyzed by icELISA. Bars depict the mean values. Dots show the values of the individual measurements.



Western Blotting

Image 3. SARS-CoV-2 Nucleocapsid Protein at 0.5ng probed with ABIN6952435 at 1:1000 and overnight incubation at 4°C.